The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Bayer Schering Pharma's levonorgestrel-releasing intrauterine contraceptive system Mirena. The product is expected to be launched nationwide in April 2007 under the trade name Mirena 52mg. According to the German drug major, the approval is based on broad experience from international studies as well as a Japanese study program, including a large clinical trial with more than 400 Japanese women. Up to now, Mirena has been used by more than 10 million women worldwide and is registered in more than 100 countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze